The triacylglycerol content of chylomicrons and VLDL (very-low-density lipoprotein) compete for the same lipolytic pathway in the capillary beds. Although chylomicron triacylglycerols appear to be the favoured substrate for lipoprotein lipase, VLDL particles compete in numbers. Methods to quantify the specific triacylglycerol removal from VLDL and chylomicrons may involve endogenous labelling of the triacylglycerol substrate with stable isotopes in combination with arteriovenous blood sampling in humans. Arteriovenous quantification of remnant lipoproteins suggests that adipose tissue with its high lipoprotein lipase activity is a principal site for generation of remnant lipoproteins. Under circumstances of reduced efficiency in the removal of triacylglycerols from lipoproteins, there is accumulation of remnant lipoproteins, which are potentially atherogenic.
Introduction
The TAG (triacylglycerol) content of TAG-rich lipoproteins is hydrolysed in the capillary bed of tissues expressing LPL (lipoprotein lipase), which subsequently leads to the formation of remnant lipoproteins which are rapidly removed from the circulation. In this process, there is delivery of fatty acids to target tissues for nutritional homoeostasis, but inefficient removal of the remnant lipoproteins may contribute to accumulation of potentially atherogenic lipoproteins. This overview will focus on the interaction between the capillary beds where LPL is highly expressed, i.e. skeletal muscle and adipose tissue, and VLDL (very-low-density lipoprotein) and chylomicrons in the formation of remnant lipoproteins in humans.
Metabolism of VLDL TAG
The major bulk of TAG in plasma is carried by either VLDL or chylomicrons. The VLDL is produced in the liver, contains one molecule of apoB (apolipoprotein B) 100 and the core of the lipoprotein particle contains something in the range of 5-25 000 TAG molecules [1] . VLDL is arbitrarily divided into large (VLDL1) and smaller (VLDL2) particles. The secretion of VLDL1 is largely dependent on the supply of TAG (fatty acids) to the hepatocyte, but there is also a direct inhibitory effect of insulin on the secretion of VLDL1 [2] . In contrast, the secretion of VLDL2 does not appear to be dependent on the TAG substrate and the rate of secretion is not inhibited Key words: apolipoprotein, atherogenesis, capillary bed, lipoprotein remnant, postprandial state, triacylglycerol removal. Abbreviations used: Angpat-4, angiopoietin-like protein-4; apoB, apolipoprotein B; LDL, lowdensity lipoprotein; LPL, lipoprotein lipase; NEFA, non-esterified fatty acid; RLP-C, remnant-like particle cholesterol; TAG, triacylglycerol; VLDL, very-low-density lipoprotein. 1 To whom correspondence should be addressed (email Fredrik.Karpe@ocdem.ox.ac.uk).
by insulin. Once in plasma, the TAG content of VLDL1 is hydrolysed rapidly by LPL. In this delipidation pathway, VLDL1 will attain the same size and TAG content as VLDL2, but may also continue its delipidation all the way to the TAGpoorest apoB-containing lipoprotein particle in the plasma, i.e. the LDL (low-density lipoprotein) particle. Some of the VLDL1 particles will never undergo complete delipidation and may be removed from plasma as remnant particles well before attaining the LDL state [3] . In contrast, almost all nascent VLDL2 particles will be effectively delipidated to LDL [4] . Overall, the knowledge of VLDL metabolism has largely been gathered by studying lipoprotein metabolism using whole-body kinetic studies and there is a paucity of attempts to study tissue-specific VLDL TAG metabolism.
Metabolism of chylomicron TAG
The study of chylomicron TAG metabolism is complicated by very high turnover rates. The large and very TAG-rich chylomicrons secreted by the intestine begin to appear in blood approx. 1 h after oral fat intake. The half-life of the TAG content of chylomicrons has been approximated to 5 min [5] , but very little is known about the formation, compositional characteristics and site of elimination of the chylomicron remnants in humans. From studies of chylomicron kinetics in rats, it has been estimated that only approximately half of the TAG content of the chylomicron particles leaves the chylomicron particle in the process of remnant particle formation [6] . Tissue removal of such remnants via receptor-mediated uptake may therefore account for a considerable amount of TAG delivery. This is probably particularly significant in the liver, where it is thought that most remnants are removed. As these very large chylomicron remnant particles are likely to have a diameter greater than the openings in the fenestrated capillary bed of the hepatic sinusoids, various mechanisms involving assisted uptake and further local delipidation by hepatic lipase appear to be important mechanisms by which chylomicrons are eventually removed from the bloodstream [7] .
It has been suggested from studies in rodents and rabbits that the intestine also secretes a wide size range of apoB48-containing lipoproteins [8] , but detailed studies of this phenomenon have never been made in humans. Lipoproteins at the lower end of this range are likely to be secreted also in the fasted state. The relevance for TAG transport from the intestine by these smaller apoB48-containing lipoproteins is essentially unknown in humans.
The kinetic properties of chylomicron remnants are still poorly understood. One of the first attempts to study the fate of chylomicrons was made by reinjection of 131 I-labelled apoB48 and apoB100 particles [9] . Although the radioactivity disappeared extremely rapidly from reinjected apoB48, indicating that a very rapid removal of particles in the three subjects studied might reflect a true event, the interpretation of this study is hampered by the fact that reinjected and exogenously labelled material was used. It is now acknowledged that this procedure may modify the lipoproteins and thus alter the genuine biological properties. To overcome the problem of modifying lipoprotein exogenously, endogenous labelling of apoB48 can be achieved by using stable isotopes. [ 2 H 5 ]Leucine administered intravenously will be incorporated into apoB48 and, after attainment of steady state, the turnover of apoB48 particles can be quantified [10] . The overall conclusion from these studies has been that apoB48 is removed from plasma with kinetic properties similar to apoB100 (VLDL remnants). This type of study does not allow the quantification of the very rapid changes taking place just after feeding and will not help to describe the kinetic properties of the largest and most rapidly turning over apoB48 lipoproteins. Furthermore, normal steady-state kinetic solutions are by definition not applicable to the postprandial state, and there is currently no solution to non-steady-state multicompartmental modelling of apolipoprotein metabolism.
Chylomicron particles can be labelled by including vitamin A in a test meal. The intestine will incorporate retinyl esters in the core of the chylomicron and there is good evidence that this marker stays with the particle until ultimate removal from plasma. We made use of this pathway some years ago to study the kinetic properties of chylomicron removal from plasma [11] . In order to achieve a metabolically stable situation the following steps were taken. Plasmapheresis was performed in healthy subjects 4 h after ingestion of a vitamin A-containing test meal. This plasma was left untouched for 24 h and thereafter reinjected to the same subject as a bolus dose. The remaining background retinyl ester label in the plasma was negligible at the time of reinjection. Frequent blood samples were taken to trace the disappearance of retinyl esters. Concentrations of retinyl esters were determined in TAG-rich lipoprotein fractions to follow the delipidation cascade, and the data were analysed in a multicompartmental model. This study showed clearly that a major proportion of chylomicron label contained in the largest chylomicrons/chylomicron remnants left the plasma compartment without being delipidated into VLDL-sized remnant particles. This happened very rapidly, but a certain proportion of the very large chylomicrons/chylomicron remnants were either transformed into particles with a much lower half-life or delipidated into remnant fractions of the size of VLDL.
LPL interactions with TAG-rich lipoproteins
LPL is anchored to heparan sulphate on endothelial surfaces in tissues expressing the enzyme. It has been estimated that chylomicrons may bind to LPL with an affinity 50 times higher than VLDL [12] . However, this is balanced by the much higher concentration of VLDL particles, which is often 50 times higher than that of chylomicrons [13] . Accordingly, in the postprandial state, there is a complex competition for TAG lipolysis between different species of TAG-rich lipoproteins, much dependent on the actual particle number and the relative expression of LPL in the tissue. As a consequence of this competition, the concentration of VLDL1 often increases in plasma after the appearance of chylomicrons [14, 15] ; the delipidation of VLDL1 is delayed and the particles accumulate in the plasma [16] . The accumulating particles attain more cholesteryl esters by cholesteryl ester transport protein-mediated mechanisms and this may form the basis for VLDL remnant lipoprotein generation [17] . In contrast, VLDL2 is often lowered or unchanged. First, less VLDL1 is converted into VLDL2 and, secondly, VLDL2 is not a particularly good substrate for LPL, thus it is not an effective competitor for LPL with chylomicrons.
The complexity of plasma fatty acid delivery from plasma lipoprotein-carried TAG to the tissues expressing LPL is complicated further by the specific nutritional regulation of LPL. LPL activity is specifically up-regulated in adipose tissue [18] . The secretion of LPL protein from adipocytes only shows a marginal change in response to insulin (simulating fasted to fed state), whereas the proportion of LPL molecules that dimerize to eventually form active LPL expressed on endothelial surface in adipose tissue is very enhanced by insulin [19] . This regulation is now thought to be mediated by the rapid down-regulation of Angpat-4 (angiopoietin-like protein-4) by insulin in adipose tissue in which Angpat-4 inhibits the formation of active and dimerized LPL molecules [20] .
Quantification of tissue-specific VLDL and chylomicron TAG removal in humans
There is a need for local measurements to estimate tissuespecific effects of LPL on the extraction of TAG from VLDL and chylomicrons. Such measurements need to differentiate between lipoprotein species; conventional techniques used to isolate TAG-rich lipoproteins from plasma do not separate chylomicrons, chylomicron remnants and VLDL particles. We have recently used a specific labelling technique of VLDL and chylomicrons respectively to quantify the TAG extraction across human skeletal muscle and adipose tissue [21] . Chylomicrons were labelled by incorporation of stable [U- 13 C]palmitate in a test meal. This leads to specific labelling of the chylomicron TAG component. However, rapid recirculation of the label leads to loss of chylomicron specificity [22] . As the chylomicron TAGs are hydrolysed by LPL, some fatty acids will be taken up by adipose tissue and other fatty acids will appear in the NEFA (non-esterified fatty acid) fraction in plasma. NEFAs and the TAG remaining in chylomicron remnant particles will undergo removal by the liver where the fatty acids may be incorporated in the lipid droplets forming VLDL. In fact, we have clear evidence that fatty acids originating from a meal will appear in VLDL within 90 min of the oral fat intake. So there appears to be a short window of opportunity to study the tissuespecific metabolism-labelled chylomicron TAG just after their secretion from the intestine, but before any substantial degree of recirculation has taken place.
The endogenous labelling of VLDL TAG for tissuespecific studies involves intravenous infusion of stable isotope-labelled fatty acids. To distinguish this label from that of chylomicrons, we have used [ 2 H 2 ]palmitate. Intravenously infused fatty acids appear in VLDL (within less than 60 min). It is unlikely that significant quantities of this label will enter the chylomicron TAG pool.
We have recently compared the fractional extraction of VLDL TAG and chylomicron TAG using this dual-labelling process in healthy human subjects. To demonstrate the tissue specificity for VLDL and chylomicron TAG extraction, blood samples were taken from the superficial epigastric vein (specific for subcutaneous adipose tissue) and the deep forearm antecubital vein (representative of skeletal muscle) after providing the isotopically labelled fatty acids as outlined above. The fractional extraction of VLDL is approx. 5% in these subjects in adipose tissue, whereas the extraction is approx. 25% for chylomicron TAG (Figure 1 ). This demonstrates, in vivo in humans, measured under physiological conditions, that chylomicron TAG is a much preferred substrate for LPL compared with VLDL. The situation is similar in the forearm. As seen from Figure 1 , the fractional extraction of [
13 C]TAG is rapidly declining and approaching that of [ 2 H 2 ]TAG. This is likely to represent two concomitant phenomena. First, the nascent chylomicrons are turned into chylomicron remnants retaining significant proportions of the TAG label, but having reduced substrate efficiency towards LPL. Secondly, a significant proportion of the label will begin to recirculate into VLDL.
Tissue-specific formation of remnant lipoproteins
Although it has been assumed that the initial step in the formation of remnants is the sequential delipidation of TAG-rich lipoproteins, little attention has been paid to the mechanisms by which remnant lipoproteins are formed in the capillary beds. In order to study this, we have made use of an immunoaffinity method to isolate remnant-like particles identified by lack of binding to a certain monoclonal anti-apoB100 antibody (JIH) and polyclonal anti-apoAI antibody [23] . The method captures all apoB48-containing lipoproteins in plasma and a subfraction of VLDL (apoB100). In five healthy male subjects (age 30 ± 3 years and body mass index 24 ± 2 kg/m 2 ), we established arteriovenous gradients across subcutaneous tissue and the forearm as described in [21] . Blood samples were taken before and after ingestion of a standardized meal. Adipose tissue blood flow was measured by washout of injected 133 Xe and forearm muscle blood flow was assessed by strain-gauge plethysmography [21] .
The RLP-C (remnant-like particle cholesterol) concentration was determined by an immunoseparation technique (Jimro-II), made available by the Otsuka Pharmaceutical, Takasaki, Japan. A total of 10 µl of plasma was mixed with 300 µl of a lipoprotein separation medium consisting of a Sepharose gel suspension to which monoclonal antibodies directed against apoB100 and apoAI had been attached. The separation medium was gently mixed for 120 min and thereafter allowed to settle for another 15 min. The venoarterial gradient was expected to be small, and all samples were analysed in triplicate. The coefficient of variation of the RLP-C assay was 7.3%. RLP-C was measured in the fasted state and at 120, 240 and 360 min after meal intake. The mean RLP-C concentrations in arterial, forearm venous and adipose tissue venous plasma in the group of healthy men showed average RLP-C venoarterial differences across the tissues of 14 and 17% for adipose tissue and the forearm respectively. To quantify the rate of RLP-C generation across the tissue, the venoarterial difference (corrected for haematocrit) was multiplied by the blood flow.
The RLP-C generation was increased severalfold even 2 h after meal intake and remained elevated for 6 h in both adipose tissue and the forearm (Figure 2 ). The area under the curve for adipose tissue was almost twice as high in adipose tissue compared with the forearm (P = 0.037), indicating that there is a specific induction of adipose tissue generation of RLP-C in the postprandial state.
A primary finding in this work was that human adipose tissue appeared to generate more remnant lipoprotein cholesterol in the postprandial state compared with the forearm. The reasons for this are not entirely clear, although it was noted that the generation of RLP-C in adipose tissue was related to the TAG clearance of the tissue. This is consistent with the definition of remnant lipoproteins: they are formed after lipolytic removal of TAG from native TAGrich lipoproteins. It is well established that the TAG removal capacity of adipose tissue exceeds that of skeletal muscle [24] .
The operational definition of remnant lipoproteins in this work is based on immunorecognition of lipoproteins. The characteristic of the RLP separation procedure is that it isolates all the apoB48 particles and a subset of apoB100 VLDL remnants. In addition, the antibodies would capture all non-apoAI and the remaining non-apoB100 lipoproteins, but this is normally a very small fraction of cholesterol in plasma. The nature of the remnant lipoproteins generated across the tissue beds has not been determined, and this would probably be technically difficult due to the admixture with all other lipoproteins present in blood. However, it is interesting to speculate that the RLP assay as such encompasses all apoB48 particles (remnants as well as non-remnants) and any increase in remnants across the tissue must therefore derive from conversion of 'native' apoB100 VLDL into remnantlike particles with the proviso that the apoB48 particles have not undergone a specific cholesterol enrichment during the single pass through the capillary bed.
In summary, there is a distinct paucity of studies on tissuespecific metabolism of VLDL and chylomicrons in humans. However, through the use of endogenous labelling of the TAG moieties of these lipoprotein species and simultaneous arteriovenous blood sampling across human adipose tissue and skeletal muscle beds, clear differences in the metabolism of VLDL and chylomicron TAG can be demonstrated. More studies are now needed to bring these findings into the perspective of different nutritional and metabolic states of humans, as well as searching for defects in humans with TAG catabolic disorders such as Type 2 diabetes, the metabolic syndrome and certain forms of hyperlipidaemias.
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